Thus, a follow-up randomized, double-blind, placebo-controlled trial with a target enrollment of 150 patients is currently being conducted to further assess the safety and efficacy of single and multiple dose ALT-836 treatment in patients with sepsis-induced ALI/ARDS (ClinicalTrials.gov ID: NCT00879606). The gene discussed is GPT; the disease is Sepsis.